Form 8-K · Current report
AbbVie 8-K, filed Aug 18, 2026
- Filed
- CIK
- 0001551152
- Accession no.
- 0001104659-26-098367
Summary
AbbVie completed an underwritten public offering of nine series of senior notes totaling roughly $10 billion in aggregate principal, and expects to use the net proceeds to fund a portion of the cash consideration for its previously announced acquisition of Apogee Therapeutics plus related fees and general corporate purposes. If the Apogee agreement is terminated or AbbVie tells the trustee it will not pursue the acquisition, AbbVie must redeem most of the series at 101% of principal under a special mandatory redemption provision.
Key points
- The offering closed on August 18, 2026 and comprised a floating-rate series due 2028 and fixed-rate notes with coupons from 4.500% to 6.100% maturing between 2028 and 2066.
- The notes are unsecured, unsubordinated obligations of AbbVie and rank equally with its other unsecured, unsubordinated indebtedness.
- The notes are issued under a 2012 base indenture with U.S. Bank Trust Company as trustee, as supplemented by Supplemental Indenture No. 13 dated August 18, 2026.
- The special mandatory redemption at 101% of principal applies to the floating-rate, 2028, 2030, 2031, 2033, 2036 and 2038 notes, but not the 2056 or 2066 notes.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01. Other Events. On August 18, 2026, AbbVie Inc. (“AbbVie”) completed its previously announced underwritten public offering (the “Notes Offering”) of $500,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of its 4.500% senior notes due 2028 (the “2028 Notes”), $1,250,000,000 aggregate principal amount of its 4.650% senior notes due 2030 (the “2030 Notes”), $1,500,000,000 aggregate principal amount of its 4.875% senior notes due 2031 (the “2031 Notes”), $1,250,000,000 aggregate principal amount of its 5.050% senior notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.